![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1494471
ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - À¯Çü, Àç·á, µðÀÚÀÎ, ¿ëµµ, À¯Åë ä³Îº° ºÐ¼®North America Prefilled Syringe Market Forecast to 2030 - Regional Analysis - by Type, Material, Design, Application, and Distribution Channel |
ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀº 2022³â 29¾ï 9,269¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2030³â¿¡´Â 67¾ï 8,362¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2022-2030³â°£ ¿¬Æò±Õ 10.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.
¸¸¼º Áúȯ Áõ°¡·Î ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀå ¼ºÀå ÃËÁø
°í·ÉÈ Àα¸ Áõ°¡, »çȸÀû Çൿ°ú ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È´Â ÀϹÝÀûÀÎ Àå±âÀûÀÎ °Ç° »óÅÂÀÇ ÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ¸¸¼º »ýȰ½À°üº´ÀÇ À¯º´·üÀº 2026³â ¸»±îÁö 57% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÅÈï±¹¿¡¼´Â Àα¸°¡ Æø¹ßÀûÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ±â ¶§¹®¿¡ °¡Àå Å« Ÿ°ÝÀ» ¹Þ´Â °ÍÀº ½ÅÈï±¹ÀÔ´Ï´Ù. µµ½ÃȰ¡ ÁøÇàµÊ¿¡ µû¶ó »ç¶÷µéÀº ¾É¾Æ¼ »ýȰÇÏ´Â »ýȰ¹æ½ÄÀ¸·Î ÀÎÇØ ·ù¸¶Æ¼½º °üÀý¿°, ´ç´¢º´ µîÀÌ ¹ß»ýÇÏ°Ô µË´Ï´Ù. ´ç´¢º´Àº 21¼¼±â ¼¼°è º¸°Ç ¹®Á¦ Áß ÇϳªÀÔ´Ï´Ù. ±¹Á¦´ç´¢º´¿¬¸Í(IDF)¿¡ µû¸£¸é 2019³â ºÏ¹ÌÀÇ ´ç´¢º´ ȯÀÚ ¼ö´Â ¾à 4,600¸¸ ¸íÀ̸ç 2045³â¿¡´Â 6,200¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È À¯º´·ü Áõ°¡À²Àº ¾à 35%¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.
Å©·Ðº´, ´Ù¹ß¼º °æÈÁõ, ½ÉÇ÷°ü Áúȯ°ú °°Àº ´Ù¸¥ ¸¸¼º ÁúȯÀº Áúº´ °ü¸® ¹× Ä¡·á¸¦ À§ÇØ ºó¹øÇÑ ¾à¹° Åõ¿©°¡ ÇÊ¿äÇϸç, WHO¿¡ µû¸£¸é ½ÉÇ÷°ü ÁúȯÀº »ç¸Á ¿øÀÎ 1À§·Î ¸Å³â ¾à 1,790¸¸ ¸íÀÌ ½ÉÇ÷°ü ÁúȯÀ¸·Î ÀÎÇØ »ç¸ÁÇϰí ÀÖ½À´Ï´Ù. ÇÁ¸®ÇÊµå ½Ã¸°Áö´Â Àü ¼¼°èÀûÀ¸·Î ´ë±Ô¸ð ȯÀÚ Áý´Ü¿¡¼ ÁÖ»çÁ¦ Àü´ÞÀÇ »õ·Î¿î Ç¥ÁØÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ÇÁ¸®ÇÊµå ½Ã¸°Áö´Â ÃÖ¼ÒÇÑÀÇ ±³À°À¸·Î ¸¹Àº ȯÀÚ¿¡°Ô »ç¿ëÇÒ ¼ö ÀÖ°í ÀÇ·á Àü¹®°¡ÀÇ Áö¼ÓÀûÀÎ Áö¿øÀÌ ÇÊ¿äÇÏÁö ¾Ê±â ¶§¹®¿¡ Àü¹® ÀÇ·á ȯ°æ»Ó¸¸ ¾Æ´Ï¶ó ÀçÅÃÄ¡·á ȯ°æ¿¡¼µµ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀå °³¿ä/p>
ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ÀÚ°¡ÁÖ»ç¿ë ºñ°æ±¸¿ë ±â±â äÅà Áõ°¡¿Í ¸¸¼ºÁúȯ Ä¡·á¸¦ À§ÇÑ ÀçÅÃÀÇ·áÀÇ ±Þ°ÝÇÑ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.
´ç´¢º´ ¿¬±¸¼Ò¿¡ µû¸£¸é, ¹Ì±¹ ´ç´¢º´ ȯÀÚ ¼ö´Â 2022³â 3,730¸¸ ¸í(Àα¸ÀÇ 11.3%)¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹¿¡¼´Â ¾à 2,870¸¸ ¸íÀÌ ´ç´¢º´ Áø´ÜÀ» ¹Þ¾Ò°í, ¾à 860¸¸ ¸íÀÌ ´ç´¢º´ Áø´ÜÀ» ¹ÞÁö ¾Ê¾Ò½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹¿¡¼´Â ¸Å³â 140¸¸ ¸íÀÇ ´ç´¢º´ ȯÀÚ°¡ Áø´ÜÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ¿¡ µû¸£¸é 2020³â¿¡´Â ¹Ì±¹ ¼ºÀÎ Àα¸ÀÇ 34.5%¿¡ ÇØ´çÇÏ´Â 8,800¸¸ ¸íÀÇ ¼ºÀÎÀÌ ¿¹ºñ ´ç´¢º´ ȯÀÚ°¡ µÉ °ÍÀ̶ó°í ÇÕ´Ï´Ù. ¿¹ÀÏ´ë ¿¬±¸Áø¿¡ µû¸£¸é 2022³â¿¡´Â ¹Ì±¹¿¡¼ 3,000¸¸ ¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, ¾à 700¸¸ ¸íÀÌ ¸ÅÀÏ Àν¶¸°À» ÇÊ¿ä·ÎÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù.
¹Ì±¹¿¡¼´Â ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, CDC¿¡ µû¸£¸é 2022³â¿¡´Â 30¼¼ ÀÌ»ó ¿©¼º ±âÈ¥ ºÎºÎÀÇ 22%°¡ ù ¾ÆÀÌ Àӽſ¡ ¹®Á¦°¡ ÀÖÀ» °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù. ºÒÀÓ ¹®Á¦¸¦ ±Øº¹Çϱâ À§ÇØ ´Ù¾çÇÑ »çÀü ÃæÀü½Ä ÁÖ»ç±â Ä¡·á¹ýÀÌ ½ÃÀå¿¡ Ãâ½ÃµÇ°í ÀÖÀ¸¸ç, 2023³â 7¿ù ÇÁ·¹Á¦´Ï¿ì½º Ä«ºñ´Â ¿©¼º °Ç° ºÎ¹® È®´ëÀÇ ÀÏȯÀ¸·Î Á¦³×¸¯ ºÒÀÓ Ä¡·áÁ¦ÀÎ °¡´Ï·¼¸¯½º ¾Æ¼¼Å×ÀÌÆ® ÁÖ»çÁ¦ 250mcg 0.5ml¸¦ Ãâ½ÃÇÏ¿´½À´Ï´Ù. ÇÁ¸®ÇÊµå ½Ã¸°Áö ÇüÅ·ΠÃâ½ÃÇß½À´Ï´Ù. µû¶ó¼ ´ç´¢º´ ¹× ±âŸ ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Á¦Ç° Ãâ½Ã°¡ ±ÞÁõÇÏ¸é¼ ¹Ì±¹ ³» ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)
ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀå ¼¼ºÐÈ
ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀº À¯Çü, Àç·á, µðÀÚÀÎ, ¿ëµµ, À¯Åë ä³Î, ±¹°¡º°·Î ¼¼ºÐȵǾî ÀÖ½À´Ï´Ù.
À¯Çüº°·Î ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀº ÀÏȸ¿ë ÇÁ¸®ÇÊµå ½Ã¸°Áö¿Í Àç»ç¿ë °¡´ÉÇÑ ÇÁ¸®ÇÊµå ½Ã¸°Áö·Î ³ª´µ¸ç, 2022³â ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀå Á¡À¯À²Àº ÀÏȸ¿ë ÇÁ¸®ÇÊµå ½Ã¸°Áö ºÎ¹®ÀÌ ´õ Ŭ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Àç·á¿¡ µû¶ó ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀº À¯¸® ÇÁ¸®ÇÊµå ½Ã¸°Áö¿Í ÇÃ¶ó½ºÆ½ ÇÁ¸®ÇÊµå ½Ã¸°Áö·Î ¾çºÐµÇ¸ç, 2022³â ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö Á¡À¯À²Àº À¯¸® ÇÁ¸®ÇÊµå ½Ã¸°Áö ºÎ¹®ÀÌ ´õ Å®´Ï´Ù.
µðÀÚÀο¡ µû¶ó ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀº ½Ì±Û è¹ö¿Í ¸ÖƼ è¹ö·Î ³ª´¹´Ï´Ù. ´ÜÀÏ Ã¨¹ö ºÎ¹®Àº 2022³â ºÏ¹Ì¿¡¼ ´õ Å« ÇÁ¸®ÇÊµå ½Ã¸°Áö Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¿ëµµº°·Î ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀº ¾Ï, ´ç´¢º´, ÀÚ°¡¸é¿ªÁúȯ, °¨¿°Áúȯ, ±âŸ·Î ±¸ºÐµÇ¸ç, 2022³â ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀº ±âŸ ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
À¯Åë ä³Îº°·Î ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀº º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀΠä³Î·Î ±¸ºÐµË´Ï´Ù. º´¿ø ¾à±¹ ºÎ¹®Àº 2022³â ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ºÐ·ùµË´Ï´Ù. ¹Ì±¹ÀÌ 2022³â ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
B Braun SE, Shandong Weigao Group Medical Polymer Co Ltd, Gerresheimer AG, Schott AG, Nipro Corp, Becton Dickinson and Co, Baxter International Inc, Terumo Corp, Ypsomed Holding AG´Â ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö ½ÃÀå¿¡¼ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷ Áß ÀϺÎÀÔ´Ï´Ù.
The North America prefilled syringe market was valued at US$ 2,992.69 million in 2022 and is expected to reach US$ 6,783.62 million by 2030; it is estimated to record a CAGR of 10.8% from 2022 to 2030.
Increasing Prevalence of Chronic Disorders Fuels North America Prefilled Syringe Market
The growing aging population and changes in social behavior and lifestyle contribute to some of the common long-term health conditions. As per the World Health Organization (WHO), the prevalence of chronic lifestyle diseases is expected to increase by 57% by the end of 2026. The emerging markets will be hit hardest, as a population explosion is expected in developing countries. With the increasing urbanization, people are more inclined toward a sedentary lifestyle, which results in rheumatoid arthritis, diabetes, and others. Diabetes is one of the major global health issues of the 21st century. According to the International Diabetes Federation (IDF), the number of people with diabetes in North America was about 46 million in 2019 and is projected to reach 62 million by 2045. The increase in disease prevalence is approximated to be 35% during the projection period.
Other chronic conditions such as Crohn's disease, multiple sclerosis, and cardiovascular disorders require frequent drug administration for disease management and treatment. As per the WHO, cardiovascular disorders are the leading cause of death-nearly 17.9 million deaths are reported every year due to cardiovascular disorders. It has become a new standard for injectable drug delivery among large patient populations globally. Moreover, these prefilled syringes can be used by a large patient population with minimal training and do not require constant assistance from healthcare professionals, owing to which prefilled syringes are adopted largely in professional healthcare environments as well as home healthcare settings, thereby driving the prefilled syringes market growth.
North America Prefilled Syringe Market Overview
The North America prefilled syringes market is segmented into the US, Canada, and Mexico. The growth of the prefilled syringes market in the region is mainly due to the increased adoption of self-injecting parenteral devices and a surge in home healthcare to treat chronic diseases in the region.
According to the Diabetes Research Institute, the number of people with diabetes in the US was ~37.3 million (11.3% of the population) in 2022. Nearly 28.7 million people in the US were diagnosed with diabetes, and approximately 8.6 million people have undiagnosed diabetes. Further, ~1.4 million diabetes cases are diagnosed each year in the US. According to the Centers for Disease Control and Prevention, in 2020, ~88 million adults had prediabetes, which is 34.5% of the US adult population. According to Yale researchers, in 2022, ~30 million people in the US have diabetes, and about 7 million require daily insulin.
There is an increase in the demand for infertility treatment in the US. According to the CDC, in 2022, ~22% married couples, with women aged above 30 years, have problems in conceiving their first child. To overcome with infertility issues, various treatments are available in the market through prefilled syringes. In July 2023, Fresenius Kabi launched Ganirelix Acetate Injection, a generic fertility drug, in 250 mcg0.5 ml prefilled syringes as part of the company's expansion in women's health. Therefore, the increasing prevalence of diabetes and other disorders, along with surge in product launches, is expected to drive the growth of prefilled syringes market in the US.
North America Prefilled Syringe Market Revenue and Forecast to 2030 (US$ Million)
North America Prefilled Syringe Market Segmentation
The North America prefilled syringe market is segmented based on type, material, design, application, distribution channel, and country.
Based on type, the North America prefilled syringe market is bifurcated into disposable prefilled syringes and reusable prefilled syringes. The disposable prefilled syringes segment held a larger North America prefilled syringe market share in 2022.
Based on material, the North America prefilled syringe market is bifurcated into glass prefilled syringes and plastic prefilled syringes. The glass prefilled syringes segment held a larger North America prefilled syringe share in 2022.
Based on designs, the North America prefilled syringe market is bifurcated into single chamber and multi chamber. The single chamber segment held a larger North America prefilled syringe share in 2022.
In terms of application, the North America prefilled syringe market is segmented into cancer, diabetes, autoimmune disease, infectious diseases, and others. The others segment held the largest North America prefilled syringe share in 2022.
By distribution channel, the North America prefilled syringe market is segmented into hospital pharmacy, retail pharmacy, and online channel. The hospital pharmacy segment held the largest North America prefilled syringe market share in 2022.
Based on country, the North America prefilled syringe market is categorized into the US, Canada, and Mexico. The US dominated the North America prefilled syringe market in 2022.
B Braun SE, Shandong Weigao Group Medical Polymer Co Ltd, Gerresheimer AG, Schott AG, Nipro Corp, Becton Dickinson and Co, Baxter International Inc, Terumo Corp, and Ypsomed Holding AG are some of the leading companies operating in the North America prefilled syringe market.